SCHEMBL23154176

SCHEMBL23154176

CP(C)(=O)c1cc(-c2ccc(C#N)cc2)ccc1Nc1nc(Cl)ncc1Br

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ EGFR P00533 3/20 0.36
▸ MAPKAPK2 P49137 2/20 0.34
▸ IGF1R P08069 4/20 0.34
▸ INSR P06213 2/20 0.33
▸ ALK Q9UM73 2/20 0.33
▸ SCN2A Q99250 1/20 0.33
▸ SCN10A Q9Y5Y9 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ RIPK1 Q13546 1/20 0.33
▸ CDK7 P50613 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ EGLN1 Q9GZT9 2/20 0.32
▸ XDH P47989 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ PLAU P00749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23154188 0.91 RAF1 (0.38) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23153875 0.87 EGFR (0.42) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL29975976 0.87 EGFR (0.42) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23154196 0.84 EGFR (0.38) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23153842 0.83 EGFR (0.38) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23153748 0.82 EGFR (0.41) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23154240 0.82 EGFR (0.38) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23154221 0.82 MEN1 (0.39) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL23154152 0.82 ALK (0.39) MEN1KMT2AEGFRIGF1RINSR
SCHEMBL24179135 0.81 MEN1 (0.43) MEN1KMT2AEGFRIGF1RINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021057882-A1 EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR 贝达药业股份有限公司 2021-04-01 — — WO disclosed
Send feedback